[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636100":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":114,"collaborators":25,"id":116,"slug":25,"hasResults":117,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":25,"eligibilityCriteria":121,"healthyVolunteers":122,"sex":123,"minAge":124,"maxAge":125,"enrollmentInfo":126,"targetDuration":25,"studyType":129,"phases":130,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":38,"whyStopped":25,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":149},{"fullName":5,"class":6},"ModernaTX, Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose-finding Phase","EXPERIMENTAL","Participants will receive mRNA-1982 or placebo as an intramuscular injection.",[13,14],"Biological: mRNA-1982","Biological: Placebo",{"label":16,"type":10,"description":17,"interventionNames":18},"Booster Phase","Participants will receive mRNA-1982 (as a booster) or placebo as an intramuscular injection.",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"BIOLOGICAL","mRNA-1982","Suspension for injection",[16,9],null,{"type":21,"name":27,"description":23,"armGroupLabels":28,"otherNames":25},"Placebo",[16,9],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Moderna WeCare Team","CONTACT","1-866-663-3762","WeCareClinicalTrials@modernatx.com",[36,49,59,68,77,87,96,105],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":25},"Colchester Research Group","RECRUITING","Truro","Nova Scotia","B2N 1L2","Canada",{"type":44,"coordinates":45},"Point",[46,47],-63.26538,45.36685,{"lat":47,"lon":46},{"facility":50,"status":38,"city":51,"state":52,"zip":53,"country":42,"cosmosGeoPoint":54,"geoPoint":58,"contacts":25},"Bluewater Clinical Research Group Inc.","Sarnia","Ontario","N7T 4X3",{"type":44,"coordinates":55},[56,57],-82.40407,42.97866,{"lat":57,"lon":56},{"facility":60,"status":38,"city":61,"state":52,"zip":62,"country":42,"cosmosGeoPoint":63,"geoPoint":67,"contacts":25},"Stouffville Medical Research Institute Inc.","Stouffville","L4A 1H2",{"type":44,"coordinates":64},[65,66],-79.2496,43.96682,{"lat":66,"lon":65},{"facility":69,"status":38,"city":70,"state":52,"zip":71,"country":42,"cosmosGeoPoint":72,"geoPoint":76,"contacts":25},"Dr. Anil K. Gupta Medicine Professional Corporation Inc.","Toronto","M9V 4B4",{"type":44,"coordinates":73},[74,75],-79.39864,43.70643,{"lat":75,"lon":74},{"facility":78,"status":38,"city":79,"state":80,"zip":81,"country":42,"cosmosGeoPoint":82,"geoPoint":86,"contacts":25},"Diex Recherche Inc. - Division Joliette","Joliette","Quebec","J6E 6A9",{"type":44,"coordinates":83},[84,85],-73.4236,46.0164,{"lat":85,"lon":84},{"facility":88,"status":38,"city":89,"state":80,"zip":90,"country":42,"cosmosGeoPoint":91,"geoPoint":95,"contacts":25},"Diex Recherche Inc. - Division Sherbrooke","Sherbrooke","J1L 0H8",{"type":44,"coordinates":92},[93,94],-71.89908,45.40008,{"lat":94,"lon":93},{"facility":97,"status":38,"city":98,"state":80,"zip":99,"country":42,"cosmosGeoPoint":100,"geoPoint":104,"contacts":25},"Diex Recherche Inc. - Division Victoriaville","Victoriaville","G6P 3Z8",{"type":44,"coordinates":101},[102,103],-71.96579,46.05007,{"lat":103,"lon":102},{"facility":106,"status":38,"city":107,"state":25,"zip":108,"country":42,"cosmosGeoPoint":109,"geoPoint":113,"contacts":25},"Diex Recherche Inc. - Division Quebec","Québec","G1V 4T3",{"type":44,"coordinates":110},[111,112],-71.21454,46.81228,{"lat":112,"lon":111},{"type":115,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100636100",false,"NCT07561294","A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)","A Phase 2, Randomized, Observer-blind, Dose-finding, Placebo-controlled Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982, an mRNA Vaccine to Prevent Lyme Disease in Healthy Adult Participants (18 to 70 Years of Age)","Key Inclusion Criteria:\n\n* In good general health in the opinion of the investigator as determined by medical evaluation including medical history and physical examination at screening.\n* Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\nKey Exclusion Criteria:\n\n* History of anaphylaxis or severe hypersensitivity reaction requiring medical intervention after receipt of any mRNA vaccine or therapeutic or any components of an mRNA vaccine or therapeutic.\n* Have chronic illness related to Lyme disease or an active symptomatic Lyme disease infection as suspected or diagnosed by a physician.\n* Received treatment for Lyme disease within the prior 3 months.\n* Previously vaccinated against Lyme disease or participated in the past in any vaccine study for Lyme disease.\n* Had a tick bite within 4 weeks prior to Day 1.\n\nNote: Additional inclusion\u002Fexclusion criteria may apply, per protocol.",true,"ALL","18 Years","70 Years",{"count":127,"type":128},350,"ESTIMATED","INTERVENTIONAL",[131],"PHASE2","This clinical study will evaluate the safety, reactogenicity, and immunogenicity of monovalent mRNA-1982, a messenger ribonucleic acid (mRNA) vaccine to prevent Lyme disease in healthy adults aged 18 to 70 years old.",[134],"Lyme Disease",[136,22,137,138,139],"Moderna","Messenger RNA","Safety","Vaccines","2026-05-27",{"date":142,"type":143},"2026-05-28","ACTUAL",{"date":145,"type":143},"2026-04-29",{"date":147,"type":128},"2028-11-09",{"name":5,"class":6},8]